Zusammenfassung
Hintergrund
Die diabetische Retinopathie ist weiterhin eine verbreitete Komplikation des Diabetes mellitus, die aufgrund der frühen Symptomarmut ein regelmäßiges Screening verlangt.
Diagnostik
Die diagnostischen Verfahren mit permanenter Dokumentation sind zu bevorzugen, neue Technologien auf Smartphonebasis sind verfügbar.
Therapie
In der Therapie sind Stellenwert und Effektivität von normnaher Blutzucker- und guter Blutdruckeinstellung evaluiert. Die intravitreale Therapie des diabetischen Makulaödems mit Anti-VEGF-Antikörpern zeigt für einen Teil der Patienten eine gute Effektivität.
Abstract
Background
Diabetic retinopathy is still a common complication of diabetes mellitus, which necessitates regular screening due to the lack of symptoms during early stages.
Diagnostics
Diagnostic screening modalities using permanent documentation are preferable and newer technologies using smartphones are available.
Therapy
The relative role and effectiveness of euglycemia and normal blood pressure have been well defined. Intravitreal treatment of diabetic macular edema using anti-vascular endothelial growth factor (VEGF) antibodies show good effectiveness for some patients.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Thomas RL et al (2015) Prevalence of diabetic retinopathy within a national diabetic retinopathy screening service. Br J Ophthalmol 99(1):64–68
Yau JW et al (2012) Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35(3):556–564
Martin-Merino E et al (2014) Incidence of retinal complications in a cohort of newly diagnosed diabetic patients. PLoS One 9(6):e100283
Gangaputra S et al (2013) Comparison of standardized clinical classification with fundus photograph grading for the assessment of diabetic retinopathy and diabetic macular edema severity. Retina 33(7):1393–1399
Group TS (2013) Retinopathy in youth with type 2 diabetes participating in the TODAY clinical trial. Diabetes Care 36(6):1772–1774
Bourne RR et al (2013) Causes of vision loss worldwide, 1990–2010: a systematic analysis. Lancet Glob Health 1(6):e339–e349
Chew EY et al (2010) Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 363(3):233–244
Keech AC et al (2007) Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 370(9600):1687–1697
Sacks FM et al (2014) Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries. Circulation 129(9):999–1008
Kramer CK, Retnakaran R (2013) Concordance of retinopathy and nephropathy over time in Type 1 diabetes: an analysis of data from the diabetes control and complications trial. Diabet Med 30(11):1333–1341
Echouffo-Tcheugui JB et al (2013) Screening intervals for diabetic retinopathy and incidence of visual loss: a systematic review. Diabet Med 30(11):1272–1292
Russo A et al (2015) Comparison of smartphone ophthalmoscopy with slit-lamp biomicroscopy for grading diabetic retinopathy. Am J Ophthalmol 159(2):360–364
Lee CS et al (2015) Reevaluating the definition of intraretinal microvascular abnormalities and neovascularization elsewhere in diabetic retinopathy using optical coherence tomography and fluorescein angiography. Am J Ophthalmol 159(1):101–110
Schlingemann RO et al (2013) VEGF levels in plasma in relation to platelet activation, glycemic control, and microvascular complications in type 1 diabetes. Diabetes Care 36(6):1629–1634
Aiello LP, DER Group (2014) Diabetic retinopathy and other ocular findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 37(1):17–23
Hemmingsen B et al (2011) Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 343:d6898
Hemmingsen B et al (2013) Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev 11:CD008143
Do DV et al (2015) Blood pressure control for diabetic retinopathy. Cochrane Database Syst Rev 1:CD006127
Mitchell P et al (2011) The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 118(4):615–625
Schmidt-Erfurth U et al (2014) Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology 121(5):1045–1053
Brown DM et al (2013) Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 120(10):2013–2022
Korobelnik JF et al (2014) Intravitreal aflibercept for diabetic macular edema. Ophthalmology 121(11):2247–2254
Einhaltung ethischer Richtlinien
Interessenkonflikt. A. Schlotterer und H.-P. Hammes geben an, dass kein Interessenkonflikt besteht.
Alle im vorliegenden Manuskript beschriebenen Untersuchungen am Menschen wurden mit Zustimmung der zuständigen Ethik-Kommission, im Einklang mit nationalem Recht sowie gemäß der Deklaration von Helsinki von 1975 (in der aktuellen, überarbeiteten Fassung) durchgeführt. Von allen beteiligten Patienten liegt eine Einverständniserklärung vor.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schlotterer, A., Hammes, HP. Diabetes und Auge. Diabetologe 11, 292–299 (2015). https://doi.org/10.1007/s11428-015-1343-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11428-015-1343-8